Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's Unit Acquisition

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program raised a round of funding on April 06, 2016. Investors include Gilead Sciences.

Nimbus Therapeutics, formerly Nimbus Discovery, harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company's fo…

Articles about Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's Unit Acquisition: